Zimbabwe has rejected a substantial American health deal worth 367 million US dollars (£272m) over five years over Washington's request for sensitive information.
This rejection became public after a government memo dated December was leaked, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
A government spokesman has since clarified that the US was requesting biological samples for scientific study and commercial gain but refused to share the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged continued negotiations to reach a agreement agreeable to both sides so the country's vital HIV programme can continue.
Broader Background
This rejection follows a comparable situation in neighbouring Kenya, where a high court suspended a similar health funding agreement after concerns were raised about the safety of Kenyans' health data.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had administered assistance for the American government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government deals to enhance openness and responsibility.
Based on reports, Sixteen African countries have to date agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy via American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no corresponding assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"In essence, our country would supply the raw materials for medical research without any certainty that the end products would be available to our population if a future pandemic emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of bilateral deals were disrupting systems already set up through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with potential pandemics.
"This mechanism is designed to guarantee that when a nation provides its data, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our US partners on how subsequent co-operation might be arranged in a way that honours the independence and interests of both nations."
Health Experts Response
A leading public health body expressed it understood the government's concerns, but urged that talks need to persist given that much of the country's Aids initiatives were funded by external financing.
"In cases where technical issues exist, including those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," the group said.
This impasse underscores the ongoing tensions between receiving crucial international aid and safeguarding a country's data in an ever more data-driven world.